| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
215,117 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,535,908 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
319,387 |
|
|
| Total
Value |
$4,582,151 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agenus Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
994 |
2024-05-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-01 |
4 |
D |
$67.55 |
$66,267 |
D/D |
(981) |
69,156 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-05-01 |
4 |
OE |
$0.82 |
$815 |
D/D |
1,000 |
49,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-05 |
4/A |
S |
$65.52 |
$66,306 |
D/D |
(1,012) |
69,125 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
AS |
$141.90 |
$156,943 |
D/D |
(1,106) |
994 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,431 |
63,544 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
67,973 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
100,523 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2010-10-28 |
4 |
AS |
$0.96 |
$1,440 |
D/D |
(1,500) |
166,745 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2010-07-27 |
4 |
AS |
$0.93 |
$1,408 |
D/D |
(1,520) |
241,098 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-12-22 |
4 |
S |
$2.19 |
$3,391 |
D/D |
(1,548) |
47,003 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2008-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,667 |
29,689 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-12-28 |
4 |
S |
$2.09 |
$3,576 |
D/D |
(1,711) |
41,644 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2010-04-27 |
4 |
AS |
$1.16 |
$2,262 |
D/D |
(1,950) |
238,868 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2010-09-14 |
4 |
S |
$0.91 |
$1,824 |
D/D |
(2,000) |
244,098 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
2,100 |
0 |
- |
|
| AGEN |
Agenus Inc |
Director |
– • – |
2012-06-20 |
4 |
D |
$4.92 |
$10,913 |
D/D |
(2,218) |
80,372 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$130,386 |
D/D |
(2,325) |
103,832 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,424 |
2,424 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,546 |
4,970 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-04 |
4 |
OE |
$48.43 |
$124,175 |
D/D |
2,564 |
103,772 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-04 |
4 |
S |
$74.01 |
$189,762 |
D/D |
(2,564) |
101,208 |
0 |
% |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-12-27 |
4 |
S |
$2.14 |
$6,105 |
D/D |
(2,853) |
43,355 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-12-21 |
4 |
S |
$2.24 |
$6,909 |
D/D |
(3,087) |
48,551 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-06-07 |
4 |
OE |
$0.82 |
$2,730 |
D/D |
3,350 |
60,178 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-09-25 |
4 |
OE |
$0.82 |
$2,730 |
D/D |
3,350 |
56,828 |
0 |
- |
|
130 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
